Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Epistemonikos ID: 9499986f5875daf89df978294a867fa68fb63350
First added on: Apr 25, 2025